Pillo Health Launches Innovative Home Health Assistant to Dispense Medication, Track Adherence, Deliver Care Plans

 

BOSTON,  /PRNewswire/ -- Pillo Health, a Boston-based company bringing medication adherence to the forefront of healthcare, today announced the official launch of Pillo, a voice-activated in-home companion with facial recognition that lets consumers better manage their health and stay connected to their caregivers. Pillo helps users better adhere to medication regimens, reminding them about dosages at set times, and offers them research-backed care plans to remain active and empowered in improving their health.

Six in ten Americans live with at least one chronic condition, a leading driver of healthcare costs across the country. Adhering to medication to treat those conditions is especially challenging for those who have detailed, regimented care plans to follow. Medication non-adherence amounts up to $289 billion in wasted costs annually and a higher mortality rate in the U.S.

"Pillo is redefining how the industry addresses medication non-adherence and is giving people some of their independence back," said Emanuele Musini, CEO of Pillo Health. "Managing chronic conditions can create immense stress on patients and their families as day-to-day care plans can be difficult to follow and time-consuming. I wanted to create an in-home companion that helped alleviate this issue, which impacts millions of lives, particularly in the aging baby boomer population."

Pillo provides the following core services:

  • Medication Management – Pillo stores and dispenses 28 doses of medication and reminds users when to take their medications to keep them on track. Pillo also reorders medications automatically before they run out.
  • Care Plan Delivery – Pillo delivers important instructions to users to help them stay adherent to prescribed care plans by pushing personalized health content to patients at home. Pillo can play videos on its high definition screen or recite health information via voice.
  • Pillo Insights – Pillo analyzes real-time health data in order to extract valuable insights from inside the home. Pillo also serves as a connection between the caregiver and patient, by notifying the caregiver if the patient missed a dose of medication and connecting them via video.

Pillo, which is HIPAA-compliant and registered as an FDA Class 1 medical device, is already attracting attention in the healthcare community. The company received funding from Hackensack Meridian Health System's Innovation Center fund, focused on helping the startup commercialize and go-to-market in the Acute Care space. The company also completed an in-home test focused on diabetes management in partnership with AARP.

"When patients and their caregivers are discharged home from the hospital with a prescribed care plan, it is essential that they follow each step to minimize the risk of disease progression and hospital readmission," said Dr. Aiden Feng, Pillo Co-Founder and Chief Medical Officer. "Pillo is exactly what my patients need to stay on track."

To order a Pillo or to learn more about the companion, visit www.pillohealth.com. The Pillo connected mobile app, which allows consumers and caregivers to track their health data, set alerts and more is available in the App Store or Google Play.

About Pillo Health
Pillo Health offers a revolutionary new in-home digital care management platform that delivers personalized care plans for adults with chronic conditions seeking to live healthier, more independent lives at home.  The Pillo device is an interactive and engaging companion robot that stores and dispenses medication, shares patient education, guides users to follow provider-directed care plans, and connects patients to care teams and caregivers via video. Read more at www.pillohealth.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/pillo-health-launches-innovative-home-health-assistant-to-dispense-medication-track-adherence-deliver-care-plans-300759731.html

SOURCE Pillo Health

 

Back to news